Keytruda pembrolizumab: Phase II data

Top-line data from 30 evaluable patients with relapsed or refractory classical Hodgkin’s lymphoma in the open-label Phase II KEYNOTE-087 trial showed that 200 mg IV Keytruda every 3 weeks led to an ORR of 70%, including 6 complete responses and 15 partial responses, plus 6 cases of stable disease in patients who failed to respond or progressed after autologous stem cell transplantation (ASCT) and subsequent Adcetris brentuximab vedotin. In 30 evaluable patients who were ineligible for ASCT due to chemotherapy resistance and who failed to respond to Adcetris, Keytruda led to an ORR of 80%, including 8 complete responses and 16 partial responses, plus 4 cases of stable disease...